BioSpace News Archive

Coya Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, announced that it has appointed Anabella Villalobos Ph.D., Head of Biotherapeutics and Medicinal Sciences of Biogen, to the Company’s Board of Directors, effective immediately.

Pluristem Therapeutics Inc., a leading biotechnology company, announced the receipt of a “Disbursement Offer” in the amount of €20 million from the European Investment Bank.

Mesoblast Limited announced that the peer-reviewed journal Respiratory Research has published results showing that Mesoblast’s mesenchymal stromal cell product candidate remestemcel-L significantly improved respiratory and functional clinical outcomes in patients with chronic obstructive pulmonary disease and elevated levels of the inflammatory biomarker C-reactive protein.

Sanofi Canada is pleased to announce that Ontario and New Brunswick have listed DUPIXENT® on their respective provincial drug programs for the treatment of moderate-to-severe atopic dermatitis for Canadians aged 12 years and older when specific criteria are met.

Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, announced that Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, at 11:20 a.m. Eastern Time.

Insmed Incorporated Inc., a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that management will present at the following virtual investor events:

Latest funding round will support customer expansion at global scale, as well as significant investment in product and engineering

Nevakar Inc., a privately held biopharmaceutical company, announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care, acute pain management, long acting injectables and hospital infections.

Willow Biosciences Inc., a Canadian biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to announce that it will be presenting on a panel with other industry leaders at SynBioBeta’s “Celebrating Synthetic Biology Breakthroughs in Biopharma” conference on May 26, 2021.